info@seagull-health.com
SeagullHealth
search
MEXTOVI(Binimetinib)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
MEXTOVI(Binimetinib) Instructions:Uses,Dosage, Side Effects
MEXTOVI is the brand name for the active substance binimetinib, a reversible inhibitor of MEK1 and MEK2 kinases. It is formulated as 15 mg film-coated tablets for oral use. This targeted therapy is designed to interrupt the RAS/RAF/MEK/ERK signaling pathway and is exclusively used in combination with encorafenib, a BRAF inhibitor, for the treatment of eligible patients with confirmed BRAF V600E or V600K mutations.
Treatment of patients with unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation, as confirmed by an FDA-approved test.
Treatment of adult patients with metastatic NSCLC with a BRAF V600E mutation, as detected by an FDA-approved test.
Must be used in combination with encorafenib.
45 mg orally twice daily (approximately 12 hours apart) in combination with encorafenib.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- haiousales@gmail.com
